Effectiveness and safety of immune checkpoint inhibitor monotherapy in advanced upper tract urothelial carcinoma: A multicenter, retrospective, real‐world study
暂无分享,去创建一个
Minfeng Chen | Jiwei Huang | Yichu Yuan | W. Xue | Y. Bao | Q. Wei | Hailong Hu | Zaoyu Wang | Changde Fu | Zhiyang Huang | Zeyu Chen | Shuai Jiang | Ming Cai | Zhenyu Wang | Jian Huang | Xingyun Cai | Bing Zheng | Ruopeng Su | Jianming Guo | Daoping Hong | Q. Wei
[1] Minfeng Chen,et al. The efficacy and safety of first-line treatment in cisplatin-ineligible advanced upper tract urothelial carcinoma patients: a comparison of PD-1 inhibitor and carboplatin plus gemcitabine chemotherapy , 2022, Oncoimmunology.
[2] M. Milowsky,et al. The 2021 Updated European Association of Urology Guidelines on Metastatic Urothelial Carcinoma. , 2021, European urology.
[3] E. Montanari,et al. Current Knowledge on Genomic Profiling of Upper Tract Urothelial Carcinoma , 2021, Genes.
[4] N. Agarwal,et al. Immune checkpoint inhibitors in advanced upper and lower tract urothelial carcinoma: a comparison of outcomes , 2021, BJU international.
[5] G. Banna,et al. Outcome of patients with advanced upper tract urothelial carcinoma treated with immune checkpoint inhibitors: A systematic review and meta-analysis. , 2021, Critical reviews in oncology/hematology.
[6] R. Montironi,et al. Immune Checkpoint Inhibitors for the Treatment of Bladder Cancer , 2021, Cancers.
[7] S. Park,et al. Tislelizumab in Asian patients with previously treated locally advanced or metastatic urothelial carcinoma , 2020, Cancer science.
[8] F. Petros. Epidemiology, clinical presentation, and evaluation of upper-tract urothelial carcinoma , 2020, Translational andrology and urology.
[9] A. Masson-Lecomte,et al. European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2020 Update. , 2020, European urology.
[10] M. Kaag. Perioperative chemotherapy in the management of high risk upper tract urothelial cancers , 2020, Translational andrology and urology.
[11] T. Powles,et al. Biological features and clinical outcomes in atezolizumab (atezo)-treated patients (pts) with metastatic urothelial cancer (mUC) of the upper vs lower urinary tract (UTUC vs LTUC). , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.
[12] P. Hegde,et al. Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial , 2018, The Lancet.
[13] L. Collette,et al. Impact of Primary Tumor Location on Survival from the European Organization for the Research and Treatment of Cancer Advanced Urothelial Cancer Studies , 2017, The Journal of urology.
[14] Muhammad S. Khan,et al. Landmarks in the treatment of muscle-invasive bladder cancer , 2017, Nature Reviews Urology.
[15] Y. Lotan,et al. A Multi‐Institutional Comparison of Clinicopathological Characteristics and Oncologic Outcomes of Upper Tract Urothelial Carcinoma in China and the United States , 2017, The Journal of urology.
[16] K. Rau,et al. The comparison of oncologic outcomes between metastatic upper tract urothelial carcinoma and urothelial carcinoma of the bladder after cisplatin-based chemotherapy. , 2015, Urologic oncology.
[17] K. Bensalah,et al. High rates of advanced disease, complications, and decline of renal function after radical nephroureterectomy. , 2014, Urologic oncology.
[18] B. Lane,et al. Chronic kidney disease after nephroureterectomy for upper tract urothelial carcinoma and implications for the administration of perioperative chemotherapy , 2010, Cancer.
[19] Y. Lotan,et al. Outcomes of radical nephroureterectomy: A series from the Upper Tract Urothelial Carcinoma Collaboration , 2009, Cancer.
[20] F. Hamdy,et al. FGFR3 mutations indicate better survival in invasive upper urinary tract and bladder tumours. , 2009, European urology.
[21] L. Schwartz,et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.
[22] O. Cussenot,et al. Upper urinary tract urothelial cell carcinomas and other urological malignancies involved in the hereditary nonpolyposis colorectal cancer (lynch syndrome) tumor spectrum. , 2008, European urology.
[23] S. Ricci,et al. Long-Term Survival Results of a Randomized Trial Comparing Gemcitabine Plus Cisplatin, With Methotrexate, Vinblastine, Doxorubicin, Plus Cisplatin in Patients With Bladder Cancer , 2005 .
[24] C. Roehrborn,et al. Advanced transitional cell carcinoma of the upper urinary tract: patterns of failure, survival and impact of postoperative adjuvant radiotherapy. , 1998, The Journal of urology.